Your browser doesn't support javascript.
Risk of COVID-19 Among Unvaccinated and Vaccinated Patients With Rheumatoid Arthritis: A General Population Study.
Li, Hui; Wallace, Zachary S; Sparks, Jeffrey A; Lu, Na; Wei, Jie; Xie, Dongxing; Wang, Yilun; Zeng, Chao; Lei, Guanghua; Zhang, Yuqing.
  • Li H; Xiangya Hospital, Central South University, Changsha, China.
  • Wallace ZS; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
  • Sparks JA; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Lu N; Arthritis Research Canada, Richmond, British Columbia, Canada.
  • Wei J; Xiangya Hospital, Central South University, Changsha, China.
  • Xie D; Xiangya Hospital, Central South University, Changsha, China.
  • Wang Y; Xiangya Hospital, Central South University, Changsha, China.
  • Zeng C; Xiangya Hospital, Central South University, Changsha, China.
  • Lei G; Xiangya Hospital, Central South University, Changsha, China.
  • Zhang Y; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston.
Arthritis Care Res (Hoboken) ; 2022 Sep 26.
Article in English | MEDLINE | ID: covidwho-2298727
ABSTRACT

OBJECTIVE:

To determine whether patients with rheumatoid arthritis (RA) are at higher risks for SARS-CoV-2 infection and its severe outcomes before and after COVID-19 vaccination.

METHODS:

Using a UK primary care database, we conducted 2 cohort studies to compare the risks of SARS-CoV-2 infection, hospitalization, and death from COVID-19 between patients with RA and the general population according to their COVID-19 vaccination status. We used exposure score overlap weighting to balance baseline characteristics between 2 comparison cohorts.

RESULTS:

Among unvaccinated individuals, the weighted incidence rates of SARS-CoV-2 infection (9.21 versus 8.16 of 1,000 person-months), hospitalization (3.46 versus 2.14 of 1,000 person-months), and death (1.19 versus 0.62 of 1,000 person-months) were higher among patients with RA than the general population over 3 months of follow-up; the corresponding adjusted hazard ratios (HRs) were 1.10 (95% confidence interval [95% CI] 1.00-1.24), 1.62 (95% CI 1.34-1.96), and 1.88 (95% CI 1.37-2.60), respectively. Among vaccinated individuals, the weighted rates of breakthrough infection (4.17 versus 3.96 of 1,000 person-months; HR 1.10 [95% CI 1.00-1.20]) and hospitalization (0.42 versus 0.32 of 1,000 person-months; HR 1.29 [95% CI 0.96-1.75]) were higher among patients with RA than the general population over 9 months of follow-up; however, no apparent difference in the risk of these outcomes was observed over 3 and 6 months of follow-up between 2 comparison cohorts.

CONCLUSION:

Patients with RA are still at higher risks of SARS-CoV-2 infection and COVID-19 hospitalization than the general population after receiving COVID-19 vaccines. These findings support booster COVID-19 vaccinations and adherence of other preventive strategies among patients with RA.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Rheumatology Year: 2022 Document Type: Article Affiliation country: Acr.25028

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Journal subject: Rheumatology Year: 2022 Document Type: Article Affiliation country: Acr.25028